Gareth Morgan, MD, PhD, FRCP, FRCPath, and Faith Davies, MBBCh, MRCP, MD, FRCPath, both of NYU Langone Health, New York, NY, discuss the latest advances which define the next steps for myeloma research and treatment. Prof. Morgan discusses three major areas of advancement: making molecular segmentation more sensitive and specific through methods such as whole genome sequencing, an ancestral index enabling the definition of early stages of disease according to genetic complexity, and the development of novel therapies such as bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy. Prof. Davies talks on the role of measurable residual disease (MRD) testing, mass spectrometry and imaging, as well as how machine learning may become increasingly incorporated in clinical trials going forwards. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.